Dr Ana Arance received her medical degree from Universitat de Barcelona and completed her specilist training in medical oncology at Institut Català d´Oncologia. She was awarded with a Doctor in Medicine degree from University of Manchester, and a Doctor in Philosophy degree from Imperial College, London. She worked as an Associate Specialist at Christie Hospital (Manchester) and Hammersmith Hospital (London). Dr Arance joined Hospital Clínic de Barcelona in 2009 and since then she works and leads the Melanoma and other Skin Cancer Unit. She has been an Associate Professor at Universitat Autónoma de Barcelona and is a Clinical Professor at University of Barcelona. Dr Arance is a recognized clinical researcher in melanoma internationally, and leads projects at the Institute for Biomedical Research August Pi i Sunyer (IDIBAPS) with public and private funding. Her areas of expertise include immunotherapy and drug development, and has been the PI of hundreds of clinical trials. She has published extensively and has been at the forefront of the development of paradigm shifting breakthroughs, including BRAF/MEK targeted agents, antiCTLA4, antiPD/L1 therapies and adoptive cell therapy with TILs. Her current interests include new immunotherapeutic options for patients upon progression on PD1 and biomarker discovery, including bi-specific antibodies, cell therapy, and oncolytic therapies with a focus on combinatorial approaches resulting in potentially greater patient benefit. With >